Summary statistics - qualitative results

EQA round: IGIT2/24 - Immunopathology of GIT

Deadline: 18.10.2024

Setup: groups - M (measurement principle)

AV = assigned value
CVP = consensus of all participants
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV		Frequency of the results N_{tot}	N_{rel} [%]	Result	Success N_{eva}	N_{suc}	S_{rel} [%]
Set 1								
(595) **anti-gliadin IgA (deamidated)**			77			77	77	100
Sample A1			77			77	77	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Negative			
(2) EIA methods	CVP	>>>	54	70	Negative			
(5) LIA, ILMA	CVP	>>>	19	25	Negative			
(99) Another measurement principle	CVP	>>>	3	3,9	Negative			
Sample B1			77			77	77	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Positive			
(2) EIA methods	CVP	>>>	54	70	Positive			
(5) LIA, ILMA	CVP	>>>	19	25	Positive			
(99) Another measurement principle	CVP	>>>	3	3,9	Positive			
(594) **anti-gliadin IgG (deamidated)**			79			79	79	100
Sample A1			79			79	79	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Negative			
(2) EIA methods	CVP	>>>	55	70	Negative			
(5) LIA, ILMA	CVP	>>>	20	25	Negative			
(99) Another measurement principle	CVP	>>>	3	3,8	Negative			
Sample B1			79			79	79	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Positive			
(2) EIA methods	CVP	>>>	55	70	Positive			
(5) LIA, ILMA	CVP	>>>	20	25	Positive			
(99) Another measurement principle	CVP	>>>	3	3,8	Positive			
Set 2								
(424) **anti-endomysium IgA**			71			71	71	100
Sample A2			71			71	71	100
(1) Fluorescent methods	CVP	>>>	70	99	Negative			
(2) EIA methods	CVP	>>>	1	1,4	Negative			
Sample B2			71			71	71	100
(1) Fluorescent methods	CVP	>>>	70	99	Positive			
(2) EIA methods	CVP	>>>	1	1,4	Positive			
(425) **anti-transglutaminase IgA**			85			85	85	100
Sample A2			85			85	85	100
(1) Fluorescent methods	CVP	>>>	1	1,2	Negative			
(2) EIA methods	CVP	>>>	59	69	Negative			
(5) LIA, ILMA	CVP	>>>	23	27	Negative			
(99) Another measurement principle	CVP	>>>	2	2,4	Negative			
Sample B2			85			85	85	100
(1) Fluorescent methods	CVP	>>>	1	1,2	Positive			
(2) EIA methods	CVP	>>>	59	69	Positive			
(5) LIA, ILMA	CVP	>>>	23	27	Positive			
(99) Another measurement principle	CVP	>>>	2	2,4	Positive			
Set 3								
(592) **anti-Saccharomyces cerevisiae IgA**			66			66	64	97
Sample A3			66			66	66	100
(1) Fluorescent methods	CVP	>>>	24	36	Positive			
(2) EIA methods	CVP	>>>	40	61	Positive			
(5) LIA, ILMA	CVP	>>>	2	3	Positive			
Sample B3			66			66	64	97
(1) Fluorescent methods	CVP	>>>	24	36	Negative			
(2) EIA methods	CVP	>>>	38	58	Negative			
			1	1,5	Inconclusive result (borderline)			
			1	1,5	Positive			
(5) LIA, ILMA	CVP	>>>	2	3	Negative			
(593) **anti-Saccharomyces cerevisiae IgG**			59			59	58	98
Sample A3			59			59	59	100
(1) Fluorescent methods	CVP	>>>	20	34	Positive			
(2) EIA methods	CVP	>>>	37	63	Positive			
(5) LIA, ILMA	CVP	>>>	2	3,4	Positive			
Sample B3			59			59	58	98
(1) Fluorescent methods	CVP	>>>	20	34	Negative			
(2) EIA methods	CVP	>>>	36	61	Negative			
			1	1,7	Inconclusive result (borderline)			

Summary statistics - qualitative results

EQA round: IGIT2/24 - Immunopathology of GIT

Deadline: 18.10.2024

Setup: groups - M (measurement principle)

Test / Sample / Group		AV	N_{tot}	N_{rel} [%]	Result	N_{eva}	N_{suc}	S_{rel} [%]
						Frequency of the results		**Success**
(5) LIA, ILMA	CVP	>>>	2	3,4	Negative			